A. U. Ahmed

Ribonucleotide Reductase Regulatory Subunit M2 as a Driver of Glioblastoma TMZ-Resistance through Modulation of dNTP Production

This study identifies RRM2 as a driver of TMZ resistance in GBM by modulating dNTP production, showing RRM2 inhibition enhances TMZ efficacy in vivo.

CRISPR-Cas9 Screen Reveals PSMB3 Contributes to Gliomagenesis Through Proteasome-Dependent and Independent Mechanisms

The paper identifies PSMB3 as a contributor to gliomagenesis through proteasome-dependent and independent mechanisms using a CRISPR-Cas9 screen in GBM.

De-novo purine biosynthesis is a major driver of chemoresistance in glioblastoma

This study identifies de-novo purine biosynthesis as a driver of chemoresistance in glioblastoma and shows that targeting it with Mycophenolate Mofetil can enhance TMZ efficacy.

LNX1 Modulates Notch1 Signaling to Promote Expansion of the Glioma Stem Cell Population During Temozolomide Therapy in Glioblastoma

This study shows that LNX1 enhances Notch1 signaling during temozolomide therapy, promoting glioma stem cell expansion and therapeutic resistance in glioblastoma.

Interleukin-8/CXCR2 signaling regulates therapy-induced plasticity and enhances tumorigenicity in glioblastoma

This study shows IL-8 promotes cellular plasticity and therapeutic resistance in glioblastoma by altering epigenetic marks and enhancing cancer initiating cell properties.

Activation of dopamine receptor 2 (DRD2) prompts transcriptomic and metabolic plasticity in glioblastoma

This paper shows that dopamine receptor 2 activation in glioblastoma cells increases their growth, stemness, and metabolic activity, suggesting dopamine signaling as a therapeutic target.